Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Farmers Insurance
McKesson
UBS
Harvard Business School
Daiichi Sankyo
Federal Trade Commission
Chubb
Cantor Fitzgerald
Merck

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,799,331

« Back to Dashboard

Which drugs does patent 7,799,331 protect, and when does it expire?

Patent 7,799,331 protects FLO-PRED and is included in one NDA.

This patent has twelve patent family members in ten countries.
Summary for Patent: 7,799,331
Title:Oral suspension of prednisolone acetate
Abstract: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
Inventor(s): Asotra; Satish (Brampton, CA), Gao; Shen (Botton, CA), Yacobi; Avraham (Englewood, NJ)
Assignee: Taro Pharmaceutical North America, Inc. (Grand Cayman, KY)
Application Number:11/457,197
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Dosage form; Formulation;

Drugs Protected by US Patent 7,799,331

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 DISCN No No ➤ Subscribe ➤ Subscribe Y TREATMENT OF ASTHMA ➤ Subscribe
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 DISCN No No ➤ Subscribe ➤ Subscribe Y TREATMENT OF ALLERGIC REACTIONS ➤ Subscribe
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 DISCN No No ➤ Subscribe ➤ Subscribe Y TREATMENT OF ALLERGIC REACTIONS ➤ Subscribe
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 DISCN No No ➤ Subscribe ➤ Subscribe Y TREATMENT OF ASTHMA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,799,331

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,206,727 Oral suspension of prednisolone acetate ➤ Subscribe
8,461,139 Oral suspension of prednisolone acetate ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,799,331

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 566117 ➤ Subscribe
South Korea 20080044245 ➤ Subscribe
Japan 2013014634 ➤ Subscribe
Japan 2009503097 ➤ Subscribe
Israel 189257 ➤ Subscribe
European Patent Office 2630951 ➤ Subscribe
European Patent Office 1909798 ➤ Subscribe
China 101247786 ➤ Subscribe
Canada 2616112 ➤ Subscribe
Australia 2006278620 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cipla
Daiichi Sankyo
US Army
Argus Health
US Department of Justice
Medtronic
Boehringer Ingelheim
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot